Alvocidib

Search with Google Search with Bing

Information
Drug Name
Alvocidib
Description
Entry(CIViC)
1
CIViC
Disease Mutation EL ET ED CS VO TR Pubmed Links
skin melanoma CDKN2A LOSS
( ENST00000579755.2 ) CDKN2A LOSS
( ENST00000579755.2 ) 		D Predictive Supports Sensitivity/Response Somatic 2 12777976 Detail
Annotation
Description Associated Genes Associated Variants Sensitivity Supported Source Links
Preclinical study in 9 melanoma cell lines. Three ... CDKN2A CDKN2A LOSS
( ENST00000579755.2 ) CDKN2A LOSS
( ENST00000579755.2 ) 		Sensitivity true CIViC Evidence detail
NCT ID Status Phase Summary Start date Completion date
NCT03563560 Completed Phase 1 A Study of DSP-2033 (Alvocidib) in Patients With Acute Myeloid Leukemia May 15, 2018 March 31, 2020
NCT00003039 Completed Phase 2 Flavopiridol in Treating Patients With Recurrent Intermediate-Grade or High-Grade Non-Hodgkin's Lymphoma or Mantle Cell Lymphoma September 1997
NCT00003256 Completed Phase 2 Flavopiridol in Treating Patients With Recurrent Prostate Cancer May 1998 April 2004
NCT00003620 Completed Phase 2 Flavopiridol in Treating Patients With Chronic Lymphocytic Leukemia June 1999
NCT00003690 Completed Phase 1 Flavopiridol Plus Cisplatin or Carboplatin in Treating Patients With Advanced Solid Tumors December 1998 September 2003
NCT00005074 Completed Phase 2 Flavopiridol in Treating Patients With Previously Untreated or Relapsed Mantle Cell Lymphoma January 24, 2000 September 22, 2008
NCT00005971 Completed Phase 2 Flavopiridol in Treating Patients With Metastatic Malignant Melanoma July 4, 2000 December 21, 2009
NCT00005974 Completed Phase 2 Flavopiridol in Treating Patients With Recurrent, Locally Advanced, or Metastatic Soft Tissue Sarcoma July 4, 2000 September 22, 2008
NCT00006245 Completed Phase 2 Flavopiridol and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Esophageal Cancer That Has Not Responded to Previous Paclitaxel July 2000 August 2007
NCT00006485 Completed Phase 1 Flavopiridol and Irinotecan in Treating Patients With Advanced Solid Tumors September 2000
NCT00007917 Completed Phase 1 Gemcitabine Plus Flavopiridol in Treating Patients With Advanced Solid Tumors January 2001 October 2010
NCT00012181 Completed Phase 1 Flavopiridol in Treating Children With Relapsed or Refractory Solid Tumors or Lymphomas April 2001
NCT00016016 Completed Phase 1/Phase 2 Flavopiridol, Cytarabine, and Mitoxantrone in Treating Patients With Acute Leukemia February 2001
NCT00016185 Completed Phase 1 Flavopiridol and Docetaxel in Treating Patients With Advanced Solid Tumors March 2001 December 2005
NCT00016939 Completed Phase 2 Flavopiridol in Treating Patients With Unresectable or Metastatic Kidney Cancer May 2001 April 2006
NCT00019344 Completed Phase 1 Flavopiridol in Treating Patients With Refractory Cancer August 1997
NCT00020189 Completed Phase 2 Flavopiridol in Treating Patients With Recurrent or Metastatic Head and Neck Cancer June 2000 August 2004
NCT00020332 Completed Phase 1/Phase 2 Docetaxel and Flavopiridol in Treating Patients With Locally Advanced or Metastatic Breast Cancer October 2000 March 2003
NCT00021073 Completed Phase 1 Combination Chemotherapy in Treating Patients With Advanced Cancer May 2001
NCT00023894 Completed Phase 2 Flavopiridol in Treating Patients With Recurrent or Persistent Endometrial Cancer July 2001 February 2006
NCT00470197 Completed Phase 1 Flavopiridol, Cytarabine, and Mitoxantrone in Treating Patients With Relapsed or Refractory Acute Leukemia April 2007
NCT00634244 Completed Phase 2 Comparing Three Different Combination Chemotherapy Regimens in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia October 2008 October 2014
NCT00795002 Completed Phase 2 Alvocidib, Cytarabine, and Mitoxantrone in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia November 2008 September 2012
NCT00991952 Completed Phase 2 Irinotecan Hydrochloride With or Without Alvocidib in Treating Patients With Advanced Stomach or Gastroesophageal Junction Cancer That Cannot Be Removed By Surgery September 2009 April 2014
NCT01349972 Completed Phase 2 Alvocidib, Cytarabine, and Mitoxantrone Hydrochloride or Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia April 2011 May 2014
NCT03298984 Completed Phase 1 Ph I Study of Alvocidib and Cytarabine/Daunorubicin (7+3) in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML). September 25, 2017 March 20, 2020
NCT03441555 Completed Phase 1 A Study of Venetoclax and Alvocidib in Patients With Relapsed/Refractory Acute Myeloid Leukemia May 30, 2018 January 25, 2021
NCT00003004 Completed Phase 1 Combination Chemotherapy in Treating Patients With Refractory or Recurrent Solid Tumors July 1997 October 2001
NCT00042874 Completed Phase 1 Combination Chemotherapy in Treating Patients With Locally Advanced or Metastatic Solid Tumors May 2002
NCT00045448 Completed Phase 1 Combination Chemotherapy in Treating Patients With Advanced Solid Tumors April 2002 December 2009
NCT00046917 Completed Phase 1 Combination Chemotherapy in Treating Patients With Advanced Solid Tumors July 2002
NCT00047203 Completed Phase 2 Flavopiridol in Treating Patients With Relapsed or Refractory Multiple Myeloma September 2002
NCT00047307 Completed Phase 1 Flavopiridol Plus Radiation Therapy Followed By Gemcitabine Hydrochloride in Treating Patients With Locally Advanced, Unresectable Pancreatic Cancer August 2002
NCT00058227 Completed Phase 1 Alvocidib, Fludarabine Phosphate, and Rituximab in Treating Patients With Lymphoproliferative Disorders or Mantle Cell Lymphoma April 2003
NCT00058240 Completed Phase 1/Phase 2 Flavopiridol in Treating Patients With Previously Treated Chronic Lymphocytic Leukemia or Lymphocytic Lymphoma April 2003 February 2009
NCT00064285 Completed Phase 1 Flavopiridol and Imatinib Mesylate in Treating Patients With Hematologic Cancer June 2003
NCT00072436 Completed Phase 1 Gemcitabine Hydrochloride and Alvocidib in Treating Patients With Solid Tumors September 2003
NCT00079352 Completed Phase 1 Flavopiridol, Gemcitabine, and Irinotecan in Treating Patients With Unresectable or Metastatic Solid Tumors April 2004
NCT00080990 Completed Phase 1 Alvocidib, Oxaliplatin, Fluorouracil, and Leucovorin Calcium in Treating Patients With Advanced Solid Tumors February 2004
NCT00083122 Completed Phase 2 Cisplatin and Flavopiridol in Treating Patients With Advanced Ovarian Epithelial Cancer or Primary Peritoneal Cancer April 2004 May 2012
NCT00087282 Completed Phase 2 Irinotecan and Flavopiridol in Treating Patients With Advanced Liver Cancer June 2004 July 2006
NCT00098579 Completed Phase 1 Doxorubicin Hydrochloride and Alvocidib in Treating Patients With Metastatic or Recurrent Sarcoma That Cannot Be Removed By Surgery October 2004
NCT00278330 Completed Phase 1 Flavopiridol and Vorinostat in Treating Patients With Relapsed or Refractory Acute Leukemia or Chronic Myelogenous Leukemia or Refractory Anemia January 2006
NCT00324480 Completed Phase 1 Vorinostat and Alvocidib in Treating Patients With Advanced Solid Tumors March 2006
NCT00331682 Completed Phase 2 Docetaxel and Flavopiridol in Treating Patients With Refractory Metastatic Pancreatic Cancer March 2006 May 2008
NCT00407966 Completed Phase 2 Alvocidib, Cytarabine, and Mitoxantrone in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia October 2006 November 2009
NCT00464633 Completed Phase 2 Alvocidib in Patients With Previously Treated Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia Arising From Chronic Lymphocytic Leukemia (CLL) March 2007 December 2011
NCT00039455 Terminated Phase 1 Trastuzumab and Flavopiridol in Treating Patients With Metastatic Breast Cancer April 2002
NCT00098371 Terminated Phase 2 Flavopiridol in Treating Patients With Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia April 2005 November 2012
NCT00070239 Terminated Phase 1 Alvocidib in Treating Patients With Metastatic or Unresectable Refractory Solid Tumors or Hematologic Malignancies August 2003
NCT00377104 Terminated Phase 1 Alvocidib in Treating Patients With B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma September 2006
NCT00101231 Terminated Phase 1 Flavopiridol in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Chronic Myelogenous Leukemia October 2004
NCT00112684 Terminated Phase 1 Alvocidib in Treating Patients With Locally Advanced or Metastatic Solid Tumors February 2006
NCT00112723 Terminated Phase 1/Phase 2 Flavopiridol in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma December 2005 November 2015
NCT02520011 Terminated Phase 2 Alvocidib Biomarker-driven Phase 2 AML Study March 14, 2016 February 12, 2020